Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

Letermovir Prophylaxis Is Effective in Preventing CMV Reactivation and Is Associated with Decreased Non-Relapse Mortality in Two-Step Allogeneic Stem Cell Transplantation

Matthew J Tucker, Marc Yorker, Joanne Filicko-O'Hara, William O'Hara, Usama Gergis, Gina Keiffer, Xia Bi

Blood (2024) 144 (Supplement 1): 7320.

https://doi.org/10.1182/blood-2024-208745

Published: 2024

Journal Articles

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Julia Palecki, Maya C. Rosenberg, Jason Chen, Xiaoying Zheng, Jun Han Choi, Niti Patel, Lindsay Wilde, Gina Keiffer, Catherine E. Lai, Margaret Kasner, Chetan Jeurkar

Blood (2024) 144 (Supplement 1): 6709.

https://doi.org/10.1182/blood-2024-206072

Published: 2024

Journal Articles

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Lindsay Wilde, Chetan Jeurkar, Margaret Kasner, Neil D. Palmisiano

Blood (2024) 144 (Supplement 1): 6719.

https://doi.org/10.1182/blood-2024-210067

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Gina Keiffer, Bruno Calabretta, Alexander Mazo, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner

Blood (2023) 142 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2023-186671

Published: 2023

Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

Xia Bi, Zoe Begun, Dolores A. Grosso, Margaret Kasner, Gina Keiffer, Joanne Filicko-O'Hara, William O'Hara, John L. Wagner, Lindsay Wilde, Neal Flomenberg, Zixuan Wang, Usama Gergis

Blood (2023) 142 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2023-179931

Published: 2023

Journal Articles

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2023-186765

Published: 2023

Journal Articles

Time to Treatment for Patients with Suspected Acute Promyelocytic Leukemia (APL)

Grant Jirka, Tara Rakiewicz, Navya George, Misung Yi, Margaret Kasner, Gina Keiffer, Lindsay Wilde

Blood (2023) 142 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2023-177978

Published: 2023

Journal Articles

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Zoe Begun, Emilie Thompson, Tingting Zhan, Gina Keiffer, Margaret Kasner, Lindsay Wilde

Blood (2023) 142 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2023-184610

Published: 2023

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Gina Keiffer, Guneet Kaleka, Caspian Oliai, Lindsay Wilde, Neil Palmisiano, Margaret Kasner

Blood (2022) 140 (Supplement 1): 3320–3321.

https://doi.org/10.1182/blood-2022-170710

Published: 2022

Journal Articles

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Molly Halloran, Gina Keiffer, Veda Giri, Laura Gross, Lindsay Wilde, Neil Palmisiano, Pierluigi Porcu, Margaret Kasner

Blood (2022) 140 (Supplement 1): 11466–11467.

https://doi.org/10.1182/blood-2022-165510

Published: 2022

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140729

Published: 2020

Journal Articles

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Xia Bi, MD MS, Zachary French, MD, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141640

Published: 2020

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Gina Keiffer, MD, Kelly Hughes, Tingting Zhan, PhD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140055

Published: 2020

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

NARROW

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Letermovir Prophylaxis Is Effective in Preventing CMV Reactivation and Is Associated with Decreased Non-Relapse Mortality in Two-Step Allogeneic Stem Cell Transplantation

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Time to Treatment for Patients with Suspected Acute Promyelocytic Leukemia (APL)

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only